Eli Lilly Reports Topline Data from P-III (SURMOUNT-1) Trial of Tirzepatide to Treat Type 2 Diabetes
Shots:
- The P-III (SURMOUNT-1) trial assessed Tirzepatide (5mg, 10mg or 15mg) vs PBO to treat patients (n=1032) with type 2 diabetes with pre-diabetes and obesity or overweight of 176 wks., followed by 17 wks. without treatment, making a total of 193 weeks.
- The study showed a 94% reduced risk of progression to type 2 diabetes. The 2EPs were also reached, showing 15.4%, 19.9%, 22.9% vs 2.1% (efficacy estimand) & 12.3%, 18.7%, 19.7% vs 1.3% (treatment-regimen estimand) reduced body wt.
- This data primary analysis at 72 weeks was published in the NEJM in 2022
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
